Should You Buy Goldman Sachs Stock After Its 26% Run-Up From Its 52-Week Low?

Goldman Sachs shares trade at about $942, up 26% from their October 2025 low but 18% below the $1,152 peak reached in July, which the article characterizes as an attractive entry point at a 12.7x forward P/E. Q2 revenue rose 39% year over year to a record $20.3B, investment-banking revenue climbed 55%, and EPS surged 92% to $20.98, supported by a 48% increase in first-half 2026 global M&A volumes to $2.8T. Goldman earned roughly $100M as lead adviser on the SpaceX IPO and could receive a comparable or larger Q4 fee from the anticipated Anthropic IPO, though a Fed rate increase and management's warning of slower Q3 trading revenue remain near-term headwinds.

Analysis

The market is likely over-attributing a single marquee listing to GS earnings: even a nine-figure underwriting fee is immaterial against its quarterly revenue base and cannot offset a meaningful trading-revenue deceleration. The more investable signal is whether high-profile AI issuance broadens the sponsor-backed IPO pipeline and converts into follow-on equity, convertibles, M&A financing, and hedging flow over the next 2-4 quarters. That ecosystem effect favors GS, but also MS and JPM; GS’s relative advantage is highest if advisory and equity underwriting accelerate while fixed-income/client-trading conditions remain merely stable.

At roughly 12.7x forward earnings, GS is not optically expensive, but the multiple embeds a benign capital-markets cycle and leaves limited protection if rates stay restrictive enough to suppress deal financing or if equity volatility reduces issuance windows. The key near-term catalyst is not the IPO date itself but Q3/Q4 commentary on backlog conversion, sponsor dialogue, and trading revenue stabilization. A failure to reaffirm investment-banking momentum or a material decline in market-making revenues would likely keep the stock range-bound despite strong headline deal activity.

Contrarian view: the 18% retracement may reflect a rational normalization from unusually strong quarterly earnings rather than a clean entry point. AI-related IPOs can crowd out smaller issuers, concentrate fees among a few transactions, and create elevated execution risk if public-market aftermarket performance is weak. A poor debut would matter less to GS’s direct fee pool than to the broader reopening narrative, potentially delaying the more valuable backlog of secondary offerings and sponsor exits into 2027.

Key Decisions for Investors

• Initiate a modest 1-3 month long GS / short MS pair only if GS holds above $900 and management or peer results confirm investment-banking fee growth remains above 20% year-over-year. Target 8-12% relative upside; exit if GS reports a sequential trading-revenue decline materially worse than peers or if the pair underperforms by 7%.
• For outright exposure, wait for Q3 results rather than buying solely ahead of the listing. Add GS on evidence that advisory backlog and equity-underwriting pipeline are converting; a 2027 earnings upgrade cycle, not a one-off underwriting fee, is required for upside toward the prior high.
• Use XLF or KRE as hedges against an adverse rates/macroeconomic shock rather than shorting GS outright: GS has materially greater capital-markets beta than regional banks, while a renewed credit scare would likely pressure the entire financial complex and close issuance windows.
• Set an event alert around the first 2-4 weeks of aftermarket trading for the major AI listing. Strong liquidity and price retention would support a long GS and potentially long SPCX as a capital-markets reopening basket; weak aftermarket performance should invalidate the near-term IPO-multiple expansion thesis.